{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:18:18Z","timestamp":1761513498613,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.clbc.2014.09.009","type":"journal-article","created":{"date-parts":[[2014,10,3]],"date-time":"2014-10-03T18:41:17Z","timestamp":1412361677000},"page":"117-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Loading Dose Ibandronate Versus Standard Oral Ibandronate in Patients With Bone Metastases From Breast Cancer"],"prefix":"10.1016","volume":"15","author":[{"given":"Iain R.","family":"Macpherson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Bray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosemary A.","family":"Hannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liz-Anne","family":"Lewsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana M.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Canney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2014.09.009_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clbc.2014.09.009_bib2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/1097-0142(20000715)89:2<363::AID-CNCR22>3.0.CO;2-3","article-title":"Predictors of skeletal\u00a0complications in patients with metastatic breast carcinoma","volume":"89","author":"Domchek","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2014.09.009_bib3","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/bjc.1998.52","article-title":"Clinical course and prognostic factors following bone recurrence from breast cancer","volume":"77","author":"Coleman","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2014.09.009_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4143\/crt.2011.43.2.89","article-title":"Implications of bone-only metastases in breast cancer: favorable preference with excellent outcomes of hormone receptor positive breast cancer","volume":"43","author":"Lee","year":"2011","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.clbc.2014.09.009_bib5","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2014.09.009_bib6","first-page":"879","article-title":"Impact of skeletal complications on patients' quality of life, mobility, and functional independence","volume":"16","author":"Costa","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clbc.2014.09.009_bib7","first-page":"CD003474","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"2","author":"Wong","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clbc.2014.09.009_bib8","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2014.09.009_bib9","first-page":"653","article-title":"Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer","volume":"18","author":"Heras","year":"2009","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.clbc.2014.09.009_bib10","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.ejca.2004.03.025","article-title":"Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer","volume":"40","author":"Diel","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2014.09.009_bib11","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal\u00a0complications in breast cancer patients with metastatic bone disease: results\u00a0from two randomised, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2014.09.009_bib12","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.clbc.2014.09.009_bib13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1470-2045(13)70539-4","article-title":"Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial","volume":"15","author":"Barrett-Lee","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2014.09.009_bib14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/1745-6215-14-325","article-title":"QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates","volume":"14","author":"Nelson","year":"2013","journal-title":"Trials"},{"key":"10.1016\/j.clbc.2014.09.009_bib15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1470-2045(13)70583-7","article-title":"Which bisphosphonate to treat bone metastases?","volume":"15","author":"Costa","year":"2014","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clbc.2014.09.009_bib16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1634\/theoncologist.11-90001-27","article-title":"Ibandronate: its role in metastatic breast cancer","volume":"11","author":"Cameron","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2014.09.009_bib17","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.clbc.2014.09.009_bib18","first-page":"534","article-title":"Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease","volume":"29","author":"Bergner","year":"2006","journal-title":"Onkologie"},{"key":"10.1016\/j.clbc.2014.09.009_bib19","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1200\/JCO.2004.07.054","article-title":"Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study","volume":"22","author":"Mancini","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.clbc.2014.09.009_bib20","first-page":"S270","article-title":"High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer (abstract 897)","volume":"1","author":"Heidenreich","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2014.09.009_bib21","first-page":"396","article-title":"Efficacy of ibandronate in the management of painful osseous metastases due to hormone refractory prostate cancer (abstract A-38)","volume":"11","author":"Ohlmann","year":"2003","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clbc.2014.09.009_bib22","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000338369","article-title":"Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain","volume":"35","author":"Altundag","year":"2012","journal-title":"Onkologie"},{"key":"10.1016\/j.clbc.2014.09.009_bib23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.critrevonc.2011.02.005","article-title":"Consensus on the utility of bone markers in the malignant bone disease setting","volume":"80","author":"Coleman","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clbc.2014.09.009_bib24","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/annonc\/mdm119","article-title":"Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases","volume":"18","author":"Body","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2014.09.009_bib25","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1634\/theoncologist.12-9-1035","article-title":"Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity","volume":"12","author":"Lipton","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2014.09.009_bib26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0304-3959(83)90143-4","article-title":"Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases","volume":"17","author":"Daut","year":"1983","journal-title":"Pain"},{"year":"1985","series-title":"Applied Linear Regression. Wiley series In Probability And Mathematical Statistics. Applied Probability And Statistics","author":"Weisberg","key":"10.1016\/j.clbc.2014.09.009_bib27"},{"key":"10.1016\/j.clbc.2014.09.009_bib28","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.clbc.2014.09.009_bib29","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2014.09.009_bib30","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/sj.bjc.6604390","article-title":"Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases","volume":"98","author":"Generali","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2014.09.009_bib31","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1093\/brain\/awn116","article-title":"Placebo effects: clinical aspects and neurobiology","volume":"131","author":"Oken","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.clbc.2014.09.009_bib32","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/annonc\/mdn038","article-title":"Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study","volume":"19","author":"von Moos","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2014.09.009_bib33","first-page":"299","article-title":"Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results","volume":"15","author":"Body","year":"2006","journal-title":"Eur J Cancer Care (Engl)"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820914002018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820914002018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:14:14Z","timestamp":1761513254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820914002018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S1526820914002018"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2014.09.009","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Loading Dose Ibandronate Versus Standard Oral Ibandronate in Patients With Bone Metastases From Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2014.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}